Regulatory Movement Amid the Pandemic
The COVID-19 pandemic put a pause to most of the FDA’s in-person inspections, both domestic and foreign, for a majority of the year. In July, the FDA announced that it would resume domestic inspections, based on an advisory level framework that determines when and where it is safest to conduct them. However, there was stillRead More